Anti-BLyS/TNFSF13B antibody

Anti-BLyS/TNFSF13B antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit monoclonal to BLyS/TNFSF13B

FCM

Human BLyS / TNFSF13B

BAFF antibody; BAFF antibody; BlyS antibody; BLYS antibody; CD257 antibody; D8Ertd387e antibody; DTL antibody; MGC124060 antibody; MGC124061 antibody; TALL1 antibody; TALL1 antibody; TALL-1 antibody; TALL-1 antibody; THANK antibody; THANK antibody; Tnfsf13b antibody; TNFSF13B antibody; DTL antibody; BAFF antibody; BLYS antibody; CD257 antibody; TALL1 antibody; THANK antibody; ZTNF4 antibody; TALL-1 antibody; TNFSF20 antibody; BAFF antibody; BLyS antibody; TALL1 antibody; THANK antibody; zTNF4 antibody; TALL-1 antibody; TNFSF20 antibody; D8Ertd387e antibody; TNFSF20 antibody; TNFSF20 antibody; zTNF4 antibody; ZTNF4 antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, recombinant Human BLyS / TNFSF13B (rh BLyS / TNFSF13B; Q9Y275-1; Ala134-Leu285) and conjugated with PE under optimum conditions, the unreacted PE was removed.

Monoclonal

Aqueous solution containing 0.5% BSA and 0.09% sodium azide

This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

FCM

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

• Nardelli B, et al. (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma. 43(7): 1367-73.
• Stohl W. (2006) Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 6(4): 51-8.
• Cancro MP, et al. (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 119(5): 1066-73.